Testing a new drug to shrink liver tumors before surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a new oral medication, HRX215, given to people with colorectal cancer that has spread to the liver. The drug is taken before a procedure (portal vein embolization) that helps prepare the liver for surgery. The goal is to see if it can improve outcomes for people undergoing this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 90 years old.
- You must have colorectal cancer that has spread to the liver (liver metastases) and is considered removable by surgery.
- Your liver tumors must be measurable on a CT scan.
- You must be scheduled to have a procedure called portal vein embolization (PVE) to help your liver grow before surgery.
- Your overall health must be good enough (ECOG performance status 0-1).
- Your blood counts and liver/kidney function must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a tiny device that is placed in your liver tumor during surgery. It checks how well different chemotherapy drugs work on your specific cancer, which may help your doctor choose the best treatment for you.
This trial tests a drug called HRX215 to see if it is safe and helps the liver recover after surgery to remove colon cancer tumors that have spread to the liver. It is for people who are having either a minor or major liver resection and have a low risk of liver failure.
This trial tests a new combination of drugs for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It aims to shrink or control these liver tumors.
This trial tests two procedures—irreversible electroporation and stereotactic body radiotherapy—for people whose colorectal cancer has spread to the liver (1–3 tumors near major blood vessels or bile ducts) and can't be surgically removed or treated with heat. The goal is to see if these approaches can safely destroy those hard-to-reach tumors.
This trial is testing a combination of a new immunotherapy drug (QL1706) with chemotherapy and either cetuximab or bevacizumab for people with colorectal cancer that has spread to the liver and can potentially be removed by surgery. The goal is to shrink the tumors before surgery, making them easier to remove.
This study tests a new combination of two drugs (AK112 and VG2025) for people with colorectal cancer that has spread to the liver and has not responded to standard treatments. The goal is to see if this combination is safe and can help shrink or control the cancer.
Hear when a new Metastatic Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.